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Red Cells in the Spleen
History of Present Illness
- 79 year old man with progressive dyspnea, exertional chest 
pressure x 3 weeks; worse over the past few days
- Has chronic stable pedal edema
- No PND, orthopnea, palpitations, syncope
- Went to PCP noted to be jaundiced with mild confusion; sent 
to ED for ACS rule out and further workup 
Past Medical History
•Persistent leukocytosis with flow cytometry suspicious for CLL 
but no formal diagnosis
•Paroxysmal atrial fibrillation
•Hypertension
•Hypothyroidism
•Type 2 Diabetes Mellitus 
•Gout
Physical Exam
•VS: HR 74 RR 16 Temp 36.8 BP 107/51 O2 100% RA 
•Gen: Elderly man in no acute distress, mildly jaundiced
•Pulm: No increased WOB, CTAB
•Cardio: RRR w/ 2/6 systolic murmur best heard at the LUSB. 
No JVD
•Abd: Active bowel sounds, non-tender, splenomegaly
•Bilateral pedal edema with venous stasis changes
•Neuro: Intermittently confused but oriented x4. CN2-12 
intact. No focal findings
Labs and Imaging
•Leukocytosis with WBC 20.8, 80% lymphocytes, 3% atypical 
lymphocytes
•Severe anemia with Hgb 5.1, MCV 115. Normal platelets. 
•Total bilirubin 4.1, normal LFTs
•Haptoglobin < 30, LDH 235, DAT +complement/IgG, retic 
count 7.3%
•Negative troponin, BNP 172, EKG NSR with no significant 
changes 
•CTA negative for PE
•CT abd/pelvis with cholelithiasis and splenomegaly 
Hospital Course
• Given 95 mg of prednisone in the ED. PRBC ordered
• Lab was unable to find compatible blood; was given 3 units 
ABO and RhD compatible blood over 4 hours with 
premedication and careful monitoring for transfusion 
reaction
• Hbg responded appropriately to transfusion
• Started on 80 mg Prednisone daily
• LDH, reticulocyte count, Tbili downtrended
• Hgb remained stable
• 1 episode of recurrent chest discomfort while straining to 
have a bowel moment but otherwise asymptomatic for 
remainder of hospital course
• Discharged on 80 mg qd prednisone with outpatient 
oncology follow up
•Now following with oncology
•Flow cytometry and FISH analysis confirmed CLL diagnosis; 
monotypic B-cell population 
•FISH positive for deletion of 13q14 with no other abnormalities
•This is the most common deletion in CLL (reported in 10-20% of 
cases with conventional cytogenetics and 64% by FISH analysis)
•When present as sole abnormality this deletion is associated 
with a good prognosis with median survival longer than for CLL 
patients with normal karyotype
•Started on Ibrutinib
•Will continue prednisone until Hgb >10, then began slow taper 
over course of 4-6 months
•PJP prophylaxis with Bactrim while on high dose steroids; also 
Folic acid, Protonix
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Patients with chronic lymphocytic leukemia have a 5-
10% risk of developing autoimmune complications, the 
most common of which is autoimmune hemolytic 
anemia. Here we present a case of AIHA in a patient 
with suspected CLL that underscores several of the 
diagnostic and treatment challenges unique to this 
process. 
In virtually all cases of warm AIHA cross-matches will 
be incompatible 
•Auto-antibodies will recognize blood group antigens and react 
to the vast majority of donor red cells. Consequently, ABO and 
RhD matched blood should be given in severe anemia requiring 
urgent blood transfusion. 
•The blood should be given slowly with careful monitoring for 
transfusion reaction, though the risk of this is low (approaching 
zero without previous sensitization to foreign antigens; less 
than 10% with previous transfusion or pregnancy
There is a substantial risk of VTE in patients with AIHA, 
15-30%
•It is important to evaluate for concomitant PE in patients 
presenting with AIHA, especially as these patients also 
frequently present with dyspnea, hypoxia and tachycardia
AIHA is often a chronic, relapsing condition.
•Steroid courses of at least 6 months as well as the addition of 
Rituximab can decrease recurrences of AIHA
Lymphoproliferative disorders, and specifically CLL, are 
the most common cause of secondary warm AIHA.
•Given relatively high rate of AIHA in CLL workup for 
hematologic malignancy should be considered in patients 
presenting with apparently idiopathic AIHA.
Mean age at AIHA onset 53.6 ± 22.8 years (mean ± SD) 
Percent females 50%
Clinical symptoms at onset 87%
Anemia-related symptoms 75%
Jaundice/dark urine 33%
Chest pain/coronary syndrome 7%
Venous thrombosis 20%
Mean hemoglobin at onset 6.4 ± 1.7 g/dL 
Mean reticulocytes at onset 285 ± 175 x 103/microL 
MCV at onset 108 ± 14 fL 
Decreased haptoglobin 93%
Increased LDH 93%
Increased bilirubin 82%
Spherocytes at onset 41%
Direct antiglobulin test positivity 100%
Secondary cause present 62%
Lymphoproliferative disorder 33%
Autoimmune disorder 14%
Miscellaneous disorders 14%
(UC, immunodeficiency,
HCV, CA, drug)
Coombs Testing
Outpatient Course
Common causes of hemolysis in adults
Extravascular destruction of red blood cells
Intrinsic red blood cell defects
Enzyme deficiencies (eg, G6PD, pyruvate kinase)
Hemoglobinopathies (eg, sickle cell disease, thalassemias)
Membrane defects (eg, hereditary spherocytosis)
Extrinsic red blood cell defects
Liver disease
Hypersplenism
Infections (eg, Bartonella, Babesia, malaria)
Oxidant agents (eg, dapsone, nitrites, aniline dyes)
Other agents (eg, lead, copper, snake and spider bites)
Autoimmune hemolytic anemia (warm- or cold-reacting, drugs)
Intravenous immune globulin infusion
Intravascular destruction of red blood cells
Microangiopathic hemolytic anemia (eg, TTP, HUS, 
aortic stenosis, prosthetic valve leak)
Transfusion reactions (eg, ABO incompatibility)
Infection (eg, clostridial sepsis, severe malaria)
Paroxysmal nocturnal hemoglobinuria
Following intravenous infusion of Rho(D) immune globulin
Following intravenous infusion with hypotonic solutions
Snake bites
Exposure to compounds with high oxidant potential (eg, copper 
poisoning, Wilson disease)
Peripheral blood smear from a patient with AIHA due to a warm-reactive immunoglobulin G (IgG) antibody. 
Highlighted are dark red, small microspherocytes (red arrows) and larger spherocytes (black arrow) (x1000). 
Many large, irregular, blue-tinted red cells are also present, representing reticulocytes (blue arrows).
